Designing novel immunocombinations in metastatic renal cell carcinoma

Matteo Santoni, Francesco Massari, Gaetano Aurilio, Veronica Mollica, Alessia Cimadamore, Antonio Lopez-Beltran, Liang Cheng, Nicola Battelli, Franco Nolé, Rodolfo Montironi

Research output: Contribution to journalReview articlepeer-review


Immune checkpoint inhibitors have radically changed the treatment approach to metastatic renal cell carcinoma (mRCC). In the present article, we reported and discussed the available data with immunocombinations in mRCC, offering new perspectives in the treatment landscape of these patients. We discussed the main results of pivotal clinical trials of immune checkpoint inhibitors in the treatment of mRCC. Moreover, we discussed novel immuno-based treatments currently under investigation in ongoing clinical trials. Renal cell carcinoma is a particularly immunogenic tumor and immunotherapy is a pivotal treatment approach. A wide series of clinical trials is exploring novel promising immunocombinations in patients with renal cell carcinoma.

Original languageEnglish
Pages (from-to)1257-1268
Number of pages12
Issue number17
Publication statusPublished - Dec 2020


  • atezolizumab
  • avelumab
  • immunotherapy
  • ipilimumab
  • nivolumab
  • PD-1
  • PD-L1
  • pembrolizumab
  • RCC
  • renal cell carcinoma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology


Dive into the research topics of 'Designing novel immunocombinations in metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Cite this